How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms

SeaStar Medical’s Selective Cytopheretic Device (SCD) [Image courtesy of SeaStar Medical]

SeaStar Medical recently won FDA breakthrough device designation for a new way to treat hyperinflammation with technology that could help fight chronic conditions from COVID-19 infections.

The Denver-based medical developer is seeking a humanitarian device exemption for treating children with acute kidney injury (AKI) based on an FDA-funded study, SeaStar President and CEO Eric Schlorff said in an interview with Medical Design & Outsourcing.

The company is also planning a pivotal trial with around 200 adult AKI patients in early 2023, focused on reducing mortality and dialysis dependency.

SeaStar Medical CEO Eric Schlorff [Photo courtesy of SeaStar Medical]

SeaStar most recently studied the use of its Selective Cytopheretic Device (SCD) on 22…
Read more
  • 0

Device developer SeaStar Medical hires chief medical officer

Dr. Kevin Chung will be the chief medical officer of SeaStar Medical. [Photo courtesy of SeaStar Medical]SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1.

Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year.

SeaStar is set to go public in the third quarter of 2022 through a combination with special purpose acquisition company (SPAC) LMF Acquisition Opportunities (Nasdaq: LMAO).

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Device developer SeaStar Medical hires chief medical officer

Dr. Kevin Chung will be the chief medical officer of SeaStar Medical. [Photo courtesy of SeaStar Medical]

SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1.

Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year.

SeaStar is set to go public in the third quarter of 2022 through a combination with special purpose acquisition company (SPAC) LMF Acquisition Opportunities (Nasdaq: LMAO).

“Dr. Chung’s decades of practical experience with known applications of extracorporeal therapies and his service as a critical care intensivist make him uniquely positioned to lead SeaStar Medical’s clinical development programs,” SeaStar President and CEO Eric Schlorff said in a news release. “We are…

Read more
  • 0